Markets

Anti-inflammatory biotech Aquinox Pharmaceuticals sets terms for $41 million IPO

Aquinox Pharmaceuticals, a clinical-stage biotech developing novel drug candidates to treat inflammation and cancer, announced terms for its IPO on Friday. The Vancouver, Canada-based company plans to raise $41 million by offering 3.7 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Aquinox Pharmaceuticals would command a fully diluted market value of $107 million.

Aquinox Pharmaceuticals, which was founded in 2003, plans to list on the NASDAQ under the symbol AQXP. Aquinox Pharmaceuticals initially filed confidentially on November 18, 2013. Jefferies and Cowen & Company are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NLTX

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More